Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
head and neck cancer
Biotech
Avacta hits 10% response rate, adds peptide-drug conjugate arms
Avacta is stepping up development of its peptide-drug conjugate, kicking off expansion arms in multiple tumor types after seeing salivary gland data.
Nick Paul Taylor
Jan 16, 2025 8:51am
Merus touts cancer drug's strong profile with new data drop
Dec 2, 2024 11:59am
Pyxis' shares fall on lukewarm early ADC results in solid tumors
Nov 21, 2024 2:30pm
Ultimovacs cancer vaccine fails again, enters last chance saloon
Aug 6, 2024 4:14am
Immutep regains pep as cancer subgroup data show path forward
Jul 12, 2024 9:35am
Merck KGaA drops xevinapant with ph. 3 trial headed for failure
Jun 25, 2024 8:50am
